ライフサイエンスコーパス: hematopoietic stem cell transplantation

1 vival may only be achievable with allogeneic hematopoietic stem cell transplantation.

2 and 58 patients (2.7%) undergoing autologous hematopoietic stem cell transplantation.

3 Only 7 patients underwent allogeneic hematopoietic stem cell transplantation.

4 terquartile range, 10.5-124 d) in autologous hematopoietic stem cell transplantation.

5 dation involved chemotherapy with or without hematopoietic stem cell transplantation.

6 were also obtained from human recipients of hematopoietic stem cell transplantation.

7 malignancies refractory to prior allogeneic hematopoietic stem cell transplantation.

8 t disease (GVHD) is a severe complication of hematopoietic stem cell transplantation.

9 ent of TB in solid organ transplantation and hematopoietic stem cell transplantation.

10 cGVHD) is a major complication of allogeneic hematopoietic stem cell transplantation.

11 y hypertension, can be repurposed to improve hematopoietic stem cell transplantation.

12 ammation, and the only cure known to date is hematopoietic stem cell transplantation.

13 d transfusion therapy and in selected cases, hematopoietic stem cell transplantation.

14 te on infectious diseases in solid organ and hematopoietic stem cell transplantation.

15 s who are 21 years old or younger with prior hematopoietic stem cell transplantation.

16 f graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

17 r a year following the imposition of SCD via hematopoietic stem cell transplantation.

18 at malignancies in the context of allogeneic hematopoietic stem cell transplantation.

19 lude medical therapy, surgery, or allogeneic hematopoietic stem cell transplantation.

20 life-threatening complication of allogeneic hematopoietic stem cell transplantation.

21 of morbidity and mortality after allogeneic hematopoietic stem cell transplantation.

22 l reconstitution in patients with SCID after hematopoietic stem cell transplantation.

23 uartile range, 27-321) days after allogeneic hematopoietic stem cell transplantation.

24 t disease (cGVHD) is a major complication of hematopoietic stem cell transplantation.

25 al therapeutic target in patients undergoing hematopoietic stem cell transplantation.

26 Seven patients underwent hematopoietic stem cell transplantation.

27 as well as additional late effects following hematopoietic stem cell transplantation.

28 erve leukemia remission and allow subsequent hematopoietic stem cell transplantation.

29 -versus-host disease in both solid organ and hematopoietic stem cell transplantation.

30 is a frequent condition following allogeneic hematopoietic stem cell transplantation.

31 dels of virally triggered IBD and allogeneic hematopoietic stem cell transplantation.

32 pontaneous resolution to rapid relapse after hematopoietic stem cell transplantation.

33 Pulmonary complications are common following hematopoietic stem cell transplantation.

34 therapy to deplete the HSC niche to optimize hematopoietic stem cell transplantation.

35 stress syndrome development within 1 year of hematopoietic stem cell transplantation.

36 affected infant was treated with allogeneic hematopoietic stem-cell transplantation.

37 m; his immune deficit was fully corrected by hematopoietic stem-cell transplantation.

38 of later illness and death after allogeneic hematopoietic stem-cell transplantation.

39 post-transplantation immunity in allogeneic hematopoietic stem-cell transplantation.

40 th survival after unrelated-donor allogeneic hematopoietic stem-cell transplantation.

41 t strategies ranging from supportive care to hematopoietic stem-cell transplantation.

42 recipients worsen the outcome of allogeneic hematopoietic stem-cell transplantation.

43 y predict clinical outcomes after allogeneic hematopoietic stem-cell transplantation.

44 ic patients with cancer and those undergoing hematopoietic stem-cell transplantation.

45 olved platelet transfusion in the setting of hematopoietic stem-cell transplantation.

46 nd death, can be halted only with allogeneic hematopoietic stem-cell transplantation.

47 drome developed in 2,635 patients undergoing hematopoietic stem cell transplantation (5.0%).

48 At 12 months following hematopoietic stem cell transplantation, 89 patients (66

49 The success of allogeneic hematopoietic stem cell transplantation, a key treatment

50 replacement has been achieved by allogeneic hematopoietic stem cell transplantation, a procedure ham

51 During hematopoietic stem cell transplantation, a substantial n

52 In hematopoietic stem cell transplantation, acute graft-ver

53 rtality compared with 2.4% mortality for non-hematopoietic stem cell transplantation admissions (odds

54 ses can eradicate lymphomas after allogeneic hematopoietic stem cell transplantation (AHSCT), but can

55 inical trial of reduced-intensity allogeneic hematopoietic stem cell transplantation (AHSCT), Myelopr

56 transcript levels could identify allogeneic hematopoietic stem cell transplantation (allo- HSCT) t(8

57 -versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HCT) by su

58 intestinal toxemia botulism in an allogeneic hematopoietic stem cell transplantation (allo-HCT) recip

59 g immunological complication after allogenic hematopoietic stem cell transplantation (allo-HCT).

60 Patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) are

61 have been successfully treated by allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in c

62 Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a

63 Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is b

64 ytes, it has been speculated that allogeneic hematopoietic stem cell transplantation (allo-HSCT) may

65 In allogeneic hematopoietic stem cell transplantation (allo-HSCT), the

66 ent complication in recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT), who

67 sus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT).

68 has not been investigated during allogeneic hematopoietic stem cell transplantation (allo-HSCT).

69 isease (GVHD) in a mouse model of allogeneic hematopoietic stem cell transplantation (allo-HSCT).

70 e risk of severe infections after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

71 of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

72 Although allogeneic hematopoietic stem cell transplantation (allo-SCT) is po

73 chromosome to chemotherapy or to allogeneic hematopoietic stem-cell transplantation (allo-HSCT) acco

74 ostatus on the overall outcome of allogeneic hematopoietic stem-cell transplantation (allo-HSCT).

75 Reporting allogeneic hematopoietic stem cell transplantation (alloHSCT) outco

76 the leading cause of death after allogeneic hematopoietic stem-cell transplantation (alloHSCT).

77 t-versus-leukemia (GVL) effect in allogeneic hematopoietic stem cell transplantation (alloSCT) is pot

78 terquartile range, 15.1-139 d) in allogeneic hematopoietic stem cell transplantation and 14.2 days (i

79 in 75 patients (15.6%) undergoing allogeneic hematopoietic stem cell transplantation and 58 patients

80 D) is a notorious complication of allogeneic hematopoietic stem cell transplantation and causes disab

81 eatment of severe immunodeficiency with both hematopoietic stem cell transplantation and gene therapy

82 Trials of hematopoietic stem cell transplantation and gene therapy

83 s of UM171 make it a potential candidate for hematopoietic stem cell transplantation and gene therapy

84 been reported after definitive therapy with hematopoietic stem cell transplantation and gene therapy

85 systemic mastocytosis, including allogeneic hematopoietic stem cell transplantation and multikinase

86 After hematopoietic stem cell transplantation and other lympho

87 phoid population recovering after allogeneic hematopoietic stem cell transplantation and play a cruci

88 a life-threatening impediment to allogeneic hematopoietic stem cell transplantation, and current the

89 GVHD) is the main complication of allogeneic hematopoietic stem cell transplantation, and many effort

90 ency (SCID) can be cured by using allogeneic hematopoietic stem cell transplantation, and the absence

91 Furthermore, we took a hematopoietic stem cell transplantation approach to gene

92 Autologous hematopoietic stem cell transplantation (auto-HSCT) has

93 lt lymphoma survivors (LSs) after autologous hematopoietic stem-cell transplantation (auto-HCT) and t

94 with hematologic malignancies who underwent hematopoietic stem cell transplantation, B-1 cells were

95 In a murine model of hematopoietic stem cell transplantation, CAR-modified Tr

96 After hematopoietic stem cell transplantation, CD69(+)CXCR6(+)

97 After hematopoietic stem cell transplantation, chronic graft v

98 ts should be offered consultation to discuss hematopoietic stem cell transplantation close to the tim

99 Allogeneic hematopoietic stem cell transplantation combines cytored

100 outcomes for patients undergoing allogeneic hematopoietic stem cell transplantation continue to impr

101 cute respiratory distress syndrome following hematopoietic stem cell transplantation do not meet crit

102 s in patients treated early after allogeneic hematopoietic stem cell transplantation do not support t

103 yndrome is a frequent complication following hematopoietic stem cell transplantation, dramatically in

104 t-related complications, donor selection for hematopoietic stem cell transplantation, evaluation of c

105 with acute myelogenous leukemia treated with hematopoietic stem cell transplantation, extended use of

106 ve been successfully treated with allogeneic hematopoietic stem cell transplantation for more than 4

107 ated umbilical cord blood provides access to hematopoietic stem cell transplantation for patients lac

108 subgroups of patients undergoing allogeneic hematopoietic stem-cell transplantation for MDS may info

109 ute myeloid leukemia who received allogeneic hematopoietic stem cell transplantation from a homozygou

110 To highlight the utility for hematopoietic stem cell transplantation, frozen samples

111 ents with naive repertoires at 9-12 mo after hematopoietic stem cell transplantation had increased di

112 ignant disorders received HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT) aft

113 ytes up to 7 months after HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT) dep

114 amma (IFN-gamma) therapy is inefficient, and hematopoietic stem cell transplantation has a poor progn

115 Hematopoietic stem cell transplantation has been used fo

116 -versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (HCT [allo-HCT])

117 (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HCT) and can pr

118 elapse remains the major cause of allogeneic hematopoietic stem cell transplantation (HCT) failure, a

119 were collected on 332 children treated with hematopoietic stem cell transplantation (HCT), enzyme re

120 Importance: During hospitalization for hematopoietic stem cell transplantation (HCT), patients

121 life-threatening complication of allogeneic hematopoietic stem cell transplantation (HCT).

122 morbidity and mortality following allogeneic hematopoietic stem cell transplantation (HCT).

123 immunity is a major problem after allogeneic hematopoietic stem cell transplantation (HCT).

124 event graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation; however, it is

125 CR at day 33, t(4;11) translocation], given hematopoietic stem cell transplantation (HSCT) (n = 66)

126 -X1 patients having undergone haploidentical hematopoietic stem cell transplantation (HSCT) and 14 SC

127 oangiopathy (TA-TMA) occurs frequently after hematopoietic stem cell transplantation (HSCT) and can l

128 n transplants, virome dynamics in allogeneic hematopoietic stem cell transplantation (HSCT) and enter

129 cute lymphoblastic leukemia safely underwent hematopoietic stem cell transplantation (HSCT) and infus

130 Autologous hematopoietic stem cell transplantation (HSCT) and mesen

131 in the context of autologous and allogeneic hematopoietic stem cell transplantation (HSCT) and to id

132 virus (EBV) infections following allogeneic hematopoietic stem cell transplantation (HSCT) are a maj

133 splastic syndrome (MDS) receiving allogeneic hematopoietic stem cell transplantation (HSCT) are cured

134 Neurological complications (NC) after hematopoietic stem cell transplantation (HSCT) are rare

135 aluated regarding eligibility for allogeneic hematopoietic stem cell transplantation (HSCT) as this i

136 common and poorly recognized complication of hematopoietic stem cell transplantation (HSCT) associate

137 Allogeneic hematopoietic stem cell transplantation (HSCT) can lead

138 ry of CMV-specific T-cell immunity following hematopoietic stem cell transplantation (HSCT) could ass

139 Hematopoietic stem cell transplantation (HSCT) cures the

140 s obliterans syndrome (BOS) after allogeneic hematopoietic stem cell transplantation (HSCT) despite t

141 ular aberrations on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for cytog

142 ity conditioning has improved survival after hematopoietic stem cell transplantation (HSCT) for hemop

143 ot et al report that autologous gene therapy/hematopoietic stem cell transplantation (HSCT) for infan

144 ent cure of an HIV-infected person following hematopoietic stem cell transplantation (HSCT) from an a

145 Allogeneic hematopoietic stem cell transplantation (HSCT) from an H

146 oangiopathy (TMA) occurring after allogeneic hematopoietic stem cell transplantation (HSCT) has a dev

147 Allogeneic hematopoietic stem cell transplantation (HSCT) has been

148 Hematopoietic stem cell transplantation (HSCT) has impro

149 anti-HBc)-positive patients after allogeneic hematopoietic stem cell transplantation (HSCT) has not b

150 ose immunosuppressive therapy and autologous hematopoietic stem cell transplantation (HSCT) have show

151 n to the remaining barrier to the success of hematopoietic stem cell transplantation (HSCT) in childr

152 ion developed recommendations for allogeneic hematopoietic stem cell transplantation (HSCT) in myelod

153 curately define the outcome after allogeneic hematopoietic stem cell transplantation (HSCT) in patien

154 Moreover, the outcome of hematopoietic stem cell transplantation (HSCT) in these

155 Hematopoietic stem cell transplantation (HSCT) is a comm

156 Allogeneic hematopoietic stem cell transplantation (HSCT) is a crit

157 Myeloablative autologous hematopoietic stem cell transplantation (HSCT) is a main

158 Hematopoietic stem cell transplantation (HSCT) is an imp

159 Autologous hematopoietic stem cell transplantation (HSCT) is common

160 The treatment of CIDs with allogeneic hematopoietic stem cell transplantation (HSCT) is compli

161 Myeloablative allogeneic hematopoietic stem cell transplantation (HSCT) is curati

162 Autologous hematopoietic stem cell transplantation (HSCT) is increa

163 Autologous hematopoietic stem cell transplantation (HSCT) is increa

164 Hematopoietic stem cell transplantation (HSCT) is the mo

165 Allogeneic hematopoietic stem cell transplantation (HSCT) is the on

166 Allogeneic hematopoietic stem cell transplantation (HSCT) is the on

167 Allogeneic hematopoietic stem cell transplantation (HSCT) is used a

168 Allogeneic hematopoietic stem cell transplantation (HSCT) is widely

169 Case reports and series suggest hematopoietic stem cell transplantation (HSCT) may benef

170 Autologous hematopoietic stem cell transplantation (HSCT) of gene-m

171 Hematopoietic stem cell transplantation (HSCT) offers cu

172 Hematopoietic stem cell transplantation (HSCT) preceded

173 Allogeneic hematopoietic stem cell transplantation (HSCT) remains t

174 Allogeneic hematopoietic stem cell transplantation (HSCT) remains t

175 Allogeneic hematopoietic stem cell transplantation (HSCT) remains t

176 Hematopoietic stem cell transplantation (HSCT) represent

177 tenance of immune tolerance after allogeneic hematopoietic stem cell transplantation (HSCT) requires

178 The outcome of allogeneic hematopoietic stem cell transplantation (HSCT) was monit

179 Finally, overall survival and outcome of hematopoietic stem cell transplantation (HSCT) were not

180 on in HIV-1 reservoirs seen after allogeneic hematopoietic stem cell transplantation (HSCT) with susc

181 Hematopoietic stem cell transplantation (HSCT) with unre

182 rophylaxis has revolutionized haploidentical hematopoietic stem cell transplantation (HSCT), allowing

183 is a major cause of illness and death after hematopoietic stem cell transplantation (HSCT), and upda

184 ely on intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT), at least

185 e graft-versus-leukemia following allogeneic hematopoietic stem cell transplantation (HSCT), but the

186 In allogeneic hematopoietic stem cell transplantation (HSCT), controll

187 In the context of hematopoietic stem cell transplantation (HSCT), mesenchy

188 has critical roles in immune cells and thus, hematopoietic stem cell transplantation (HSCT), might be

189 t and devastating complication of allogeneic hematopoietic stem cell transplantation (HSCT), posing a

190 ell-recognized complication after allogeneic hematopoietic stem cell transplantation (HSCT), standard

191 namics in patients undergoing haploidentical hematopoietic stem cell transplantation (HSCT), thereby

192 e recent advances in the field of allogeneic hematopoietic stem cell transplantation (HSCT), viral in

193 have also suggested favorable outcome after hematopoietic stem cell transplantation (HSCT).

194 ed T-cell reconstitution postirradiation and hematopoietic stem cell transplantation (HSCT).

195 potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT).

196 sease (GVHD) is a complication of allogeneic hematopoietic stem cell transplantation (HSCT).

197 cause severe complications after allogeneic hematopoietic stem cell transplantation (HSCT).

198 igh-dose melphalan-based chemotherapy before hematopoietic stem cell transplantation (HSCT).

199 remains one of the main complications after hematopoietic stem cell transplantation (HSCT).

200 DOCK8) deficiency can be cured by allogeneic hematopoietic stem cell transplantation (HSCT).

201 rimary immunodeficiencies (PIDs) who require hematopoietic stem cell transplantation (HSCT).

202 of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT).

203 ains a major late complication of allogeneic hematopoietic stem cell transplantation (HSCT).

204 nificant cause of morbidity after allogeneic hematopoietic stem cell transplantation (HSCT).

205 nt is a serious complication after allogenic hematopoietic stem cell transplantation (HSCT).

206 es cause severe infections in patients after hematopoietic stem cell transplantation (HSCT).

207 cause of treatment failure after allogeneic hematopoietic stem cell transplantation (HSCT).

208 or recurrence and infection after allogeneic hematopoietic stem cell transplantation (HSCT).

209 of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT).

210 d mortality in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT).

211 natural killer (NK) cells after HLA-matched hematopoietic stem cell transplantation (HSCT).

212 ases are associated with poor outcomes after hematopoietic stem cell transplantation (HSCT).

213 ith hematologic cancers following autologous hematopoietic stem cell transplantation (HSCT).

214 disparity between donor and recipient after hematopoietic stem cell transplantation (HSCT).

215 atients who were >1 year out from allogeneic hematopoietic stem cell transplantation (HSCT).

216 AG or ARTEMIS mutations following allogeneic hematopoietic stem cell transplantation (HSCT).

217 ease (GVHD) development following subsequent hematopoietic stem cell transplantation (HSCT).

218 or predicting IFD in recipients of pediatric hematopoietic stem cell transplantation (HSCT).

219 han the general population, especially after hematopoietic stem cell transplantation (HSCT).

220 y and mortality in patients after allogeneic hematopoietic stem cell transplantation (HSCT).

221 uccessfully underwent a sequential liver and hematopoietic stem cell transplantation (HSCT).

222 a significant burden in patients undergoing hematopoietic stem cell transplantation (HSCT).

223 tensive chemotherapy (n = 121) or autologous hematopoietic stem cell transplantation (HSCT, n = 17),

224 patients who underwent early versus delayed hematopoietic stem cell transplantation (HSCT; age, </=3

225 an initial cohort of 268 patients undergoing hematopoietic stem-cell transplantation (HSCT) and their

226 The number of long-term survivors after hematopoietic stem-cell transplantation (HSCT) for malig

227 f mutations predict outcome after allogeneic hematopoietic stem-cell transplantation (HSCT) in patien

228 Hematopoietic stem-cell transplantation (HSCT) is a pote

229 Allogeneic hematopoietic stem-cell transplantation (HSCT) is potent

230 of MDS influences the outcome of allogeneic hematopoietic stem-cell transplantation (HSCT) is unclea

231 bservational studies suggest that allogeneic hematopoietic stem-cell transplantation (HSCT) may impro

232 d immune antitumor activity after allogeneic hematopoietic stem-cell transplantation (HSCT) permits r

233 e rates for patients treated with allogeneic hematopoietic stem-cell transplantation (HSCT) will requ

234 ns in patients with cancer and recipients of hematopoietic stem-cell transplantation (HSCT).

235 resistance in 561 patients who underwent 616 hematopoietic stem cell transplantations (HSCTs) over 5

236 be avoided to secure optimal unrelated donor hematopoietic stem cell transplantations (HSCTs).

237 durable clinical remissions after allogeneic hematopoietic stem cell transplantation in 2 patients su

238 In the 78 patients who received allogeneic hematopoietic stem cell transplantation in CR2, GO befor

239 The role of hematopoietic stem cell transplantation in indolent lymp

240 The thymus plays a key role post allogeneic hematopoietic stem cell transplantation in the generatio

241 Over 2,500 children undergo hematopoietic stem cell transplantation in the United St

242 , providing a rationale to potentially avoid hematopoietic stem-cell transplantation in this subset o

243 ven responders (44%) proceeded to allogeneic hematopoietic stem-cell transplantation, including 55% (

244 comes for patients with different underlying hematopoietic stem cell transplantation indications, and

245 emia (AML) can only be cured when allogeneic hematopoietic stem-cell transplantation induces a graft-

246 Hematopoietic stem cell transplantation is a potential c

247 ons, genetic screening of related donors for hematopoietic stem cell transplantation is critical, and

248 Allogeneic hematopoietic stem cell transplantation is hampered by c

249 The utility of allogeneic hematopoietic stem cell transplantation is limited by gr

250 , postremission chemotherapy with or without hematopoietic stem cell transplantation is necessary to

251 ntrol in severely affected patients for whom hematopoietic stem cell transplantation is not available

252 ed boys during the first year of life unless hematopoietic stem cell transplantation is provided.

253 Hematopoietic stem cell transplantation is the current s

254 Hematopoietic stem cell transplantation is the standard

255 Hematopoietic stem cell transplantation is the treatment

256 Although hematopoietic stem-cell transplantation is widely perfor

257 In utero hematopoietic stem cell transplantation (IUHCT) is a nov

258 n of protoporphyrin in the liver, LT without hematopoietic stem cell transplantation leaves the new l

259 onic graft-versus-host disease (cGvHD) after hematopoietic stem cell transplantation may have clinica

260 -21 in controlling immune homeostasis, early hematopoietic stem cell transplantation might be conside

261 mune suppressants, etoposide, and allogeneic hematopoietic stem cell transplantation; more than 50% o

262 (HTx, n=57), renal transplantation (n=1), or hematopoietic stem cell transplantation (n=21).

263 Two children received hematopoietic stem cell transplantation of cord blood an

264 Despite normal numbers of hematopoietic stem cells, transplantation of Fubp1(-/-)

265 Hematopoietic stem cell transplantation or gene therapy

266 MPS I is currently treated with hematopoietic stem cell transplantation or weekly enzyme

267 ing chemotherapy, immunosuppressive therapy, hematopoietic stem cell transplantation, or solid organ

268 Pediatric hematopoietic stem cell transplantation patients compris

269 PICU mortality for pediatric hematopoietic stem cell transplantation patients may be

270 e interventions, and mortality for pediatric hematopoietic stem cell transplantation patients requiri

271 signaling assays of 30 primary samples from hematopoietic stem cell transplantation patients with an

272 patients including 45 extensive cGvHD and 42 hematopoietic stem cell transplantation patients without

273 missing enzyme (enzyme replacement therapy, hematopoietic stem cell transplantation, pharmacological

274 Although hematopoietic stem-cell transplantation provides modest

275 On the contrary, long-term allogeneic hematopoietic stem cell transplantation recipients other

276 All allogeneic hematopoietic stem cell transplantation recipients treat

277 focused on MSC treatment of adult allogeneic hematopoietic stem cell transplantation recipients with

278 5% in patients with solid tumors to 1.55% in hematopoietic stem cell transplantation recipients.

279 rome but has not been assessed in allogeneic hematopoietic stem cell transplantation recipients.

280 neutropenia (FN) in children with cancer and hematopoietic stem-cell transplantation recipients.

281 ive disease, poor cytogenetics, age, year of hematopoietic stem-cell transplantation, reduced-intensi

282 esidual disease response, rate of allogeneic hematopoietic stem-cell transplantation, relapse-free su

283 Allogeneic hematopoietic stem cell transplantation (SCT) is the onl

284 Therefore, allogeneic hematopoietic stem cell transplantation should always be

285 d graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, suggesting norm

286 oxygenation within 240 days after allogeneic hematopoietic stem cell transplantation survived compare

287 ant factor for donor selection in allogeneic hematopoietic stem cell transplantation, the molecular d

288 Hematopoietic stem cell transplantation, the only curati

289 ts died early in childhood; after allogeneic hematopoietic stem-cell transplantation, the other three

290 may lead to improved KIR-HLA mismatching in hematopoietic stem cell transplantation therapy for leuk

291 wn to influence NKG2D signaling in unrelated hematopoietic stem cell transplantation (uHSCT).

292 d from swine previously rendered chimeric by hematopoietic stem cell transplantation using recipient-

293 ith relapsing-remitting MS, nonmyeloablative hematopoietic stem cell transplantation was associated w

294 Until recently, hematopoietic stem cell transplantation was the only cur

295 high-risk pediatric patients with ALL after hematopoietic stem-cell transplantation was not affected

296 ved long-term remission following allogeneic hematopoietic stem cell transplantation were monitored f

297 act on 201 patients who underwent allogeneic hematopoietic stem cell transplantation were reviewed.

298 patients with pediatric cancer or undergoing hematopoietic stem cell transplantation when used as scr

299 HD) is a major complication after allogeneic hematopoietic stem cell transplantation which causes hig

300 d with CNS disease and was reduced following hematopoietic stem cell transplantation, which is the on